EL7.AI
StocksMediumUpdated×2•Originally published 12 November 2026•Updated 12 November 2026•
3 min read

Cellebrite’s Non-GAAP Earnings Beat Estimates by $0.07 a Share

Key Facts

1Diluted earnings per share were $0.10 under GAAP and $0.17 on a non-GAAP basis in the third quarter of 2026.
2Third-quarter 2026 non-GAAP earnings per share beat analysts’ estimate by $0.07 a share.
3Second-quarter revenue was $131.1 million, up 16% year over year, while ARR reached $507.8 million, up 21%.
4In August, the company set its annual ARR outlook at $550–560 million, revenue at $555–561 million, and adjusted EBITDA at $153–159 million.

Cellebrite reported third-quarter 2026 results on November 12, with diluted earnings per share of $0.10 under GAAP and $0.17 on a non-GAAP basis. The latter beat analysts’ estimate of $0.10 by $0.07 a share, according to a Reuters report carried by Investing.com. Revenue, however, fell short of the average estimate, the same report said. The results came as markets track recurring revenue growth and signs of a shift in the company’s business. A nearly 6% rise in the stock during the results-day session could not be verified, so no price move is attributed to the report.

As prior context, second-quarter results showed revenue of $131.1 million, up 16% year over year, while annual recurring revenue (ARR) reached $507.8 million, up 21% year over year. The company had cut its annual outlook for both ARR and revenue at the time. In August, it set its fiscal 2026 ARR outlook at $550–560 million and revenue at $555–561 million. At the same time, it raised its adjusted EBITDA outlook to $153–159 million. These figures provide the financial guidance context that preceded the third-quarter results; they are not results for the current period.

After the second-quarter results, Chief Executive Shiv Ramji said ARR came in below the company’s expectations because of longer sales cycles and less-than-expected expansion in Inseyets conversions. He added that the company was taking steps to improve execution. Chief Financial Officer David Barter also said the company had lowered its annual ARR and revenue outlook but raised its adjusted EBITDA target for the year. Barter said, "We lowered our full-year ARR outlook, and the resulting impact on our revenue target, but raised our original adjusted EBITDA target for the year." These comments explain the August guidance revisions ahead of the third-quarter results.

In August, Cellebrite announced the availability of Genesis for Enterprise and expanded its regional availability to Australia and the United Kingdom. The company said at the time that availability in the European Union was expected later that month. This development forms part of the product backdrop ahead of management’s account of Genesis gaining momentum in its first full quarter. At the time of the third-quarter results, the chief executive linked revenue growth to strong international performance, further acceleration in the U.S. federal sector and momentum in Genesis. The statement did not identify demand for digital forensics products as the cause of the stock move.

The results were scheduled for release, and the investor call for Thursday, November 12, 2026, at 8:30 a.m. Eastern time, according to an investor-relations announcement. The company had set that date in advance to report its third-quarter results. The call gives management an opportunity to present results and guidance to investors and discuss business performance. The gap between adjusted earnings per share beating estimates and revenue missing its average estimate remains the most prominent element of the available results. The announcement’s effect on the stock price during the session itself has not been confirmed by a reliable open source.